Loading...
XNAS
NCNA
Market cap7kUSD
May 13, Last price  
0.03USD
1D
-17.75%
1Q
-96.17%
IPO
-99.99%
Name

NuCana PLC

Chart & Performance

D1W1MN
XNAS:NCNA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.50%
Rev. gr., 5y
%
Revenues
0k
000283,000000000
Net income
-28m
L-13.71%
0-5,332,000-6,049,000-23,085,000-13,840,000-21,412,000-30,682,000-40,533,000-32,021,000-27,632,000
CFO
-19m
L-27.69%
0-4,467,000-9,264,000-8,708,000-12,224,000-23,833,000-21,619,000-23,824,000-23,158,000-26,439,000-19,118,000
Earnings
May 15, 2025

Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
URL
https://www.nucana.com/
IPO date
Sep 28, 2017
Employees
28
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
31,125
43,717
Unusual Expense (Income)
NOPBT
(31,125)
(43,717)
NOPBT Margin
Operating Taxes
(4,398)
(6,432)
Tax Rate
NOPAT
(26,727)
(37,285)
Net income
(27,632)
-13.71%
(32,021)
-21.00%
Dividends
Dividend yield
Proceeds from repurchase of equity
8,729
249
66
BB yield
Debt
Debt current
73
206
243
Long-term debt
307
586
1,035
Deferred revenue
Other long-term liabilities
37
58
46
Net debt
(6,369)
(16,433)
(40,637)
Cash flow
Cash from operating activities
(19,118)
(26,439)
(23,158)
CAPEX
(4)
(478)
(518)
Cash from investing activities
79
2,888
120
Cash from financing activities
8,184
(53)
(161)
FCF
324
(26,382)
(37,300)
Balance
Cash
6,749
17,225
41,912
Long term investments
3
Excess cash
6,749
17,225
41,915
Stockholders' equity
(140,192)
(126,419)
38,285
Invested Capital
146,373
141,760
740
ROIC
ROCE
EV
Common stock shares outstanding
2,107
2,089
Price
Market cap
EV
EBITDA
522
(30,550)
(42,985)
EV/EBITDA
Interest
1,103
9,859
Interest/NOPBT